New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
04:55 EDTCYH, CYH, BAX, BAX, CAH, CAH, KND, KND, CRY, CRY, MDCO, MDCO, SRDX, SRDX, XOMA, XOMA, PRGO, PRGO, IDRA, IDRA, EBS, EBS, CVS, CVSRBC Capital to hold a conference
Healthcare Conference is being held in New York on February 25-26.
News For CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 18, 2015
12:24 EDTBAXBaxter sees FY16 sales growth 2%-3%
Subscribe for More Information
12:20 EDTBAXBaxter sees 2H sales growth approximately flat in constant currency
Subscribe for More Information
12:07 EDTPRGOPerrigo: there is price point where would engage with Mylan, Bloomberg reports
Subscribe for More Information
10:01 EDTCRYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:52 EDTIDRAIdera Pharmaceuticals provides development update on IMO-9200
Idera Pharmaceuticals announced the achievement of key development milestones for its product candidate IMO-9200, an antagonist of Toll-like receptors, or TLRs, 7, 8 and 9. Specifically, the company reported top-line data from a Phase 1 clinical trial of IMO-9200 in healthy subjects and announced the presentation of new preclinical data for IMO-9200 in models of inflammatory bowel disease, or IBD, at the 2015 Digestive Disease Week Conference, or DDW, in Washington, DC. In the placebo-controlled Phase 1 clinical trial in 30 healthy subjects, IMO-9200 was administered by subcutaneous injection at escalating single-dose levels of 0.1, 0.3, and 0.5 mg/kg. In the multiple dose cohort, a dose of 0.5 mg/kg/week for four weeks was also evaluated. All dose regimens were well tolerated, with no serious adverse events related to IMO-9200 treatment reported. There were no patterns of laboratory or other safety parameters suggestive of any related adverse treatment effect. Additionally, new preclinical data for IMO-9200 were presented on Saturday, May 16 at the 2015 Digestive Disease Week Conference. The poster presentation, entitled "Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Activity of Oral IMO-9200, an Antagonist of TLRs 7, 8, and 9 in Mouse Models of Colitis," provided results from two mouse models of colitis. These results demonstrated the potential of orally dosed IMO-9200 as a treatment for inflammatory bowel disease, which includes Crohn's disease, or CD, and ulcerative colitis.
08:39 EDTBAXBaxter says Baxalta separation on-track for mid-year 2015
Subscribe for More Information
07:02 EDTCRYCryoLife initiated with an Overweight at First Analysis
Target $14.
May 15, 2015
17:31 EDTBAXBaxter gets FDA approval for Spain facility to produce Sodium Chloride Injection
Subscribe for More Information
10:29 EDTCYH, CAHAmerican Urological Association to hold an annual meeting
Subscribe for More Information
10:24 EDTCYHCommunity Health management to meet with Oppenheimer
Subscribe for More Information
May 14, 2015
17:04 EDTKNDKindred Healthcare expands operations into three new states
Kindred Healthcare announced that Kindred House Calls, the company’s home-based primary care business, has expanded into three additional states. Kindred recently acquired House Call Doctors of Austin, Texas, whose CEO Julia Jung has joined Kindred’s Managed Care Group. Terms of the transaction were not disclosed. In March, Kindred acquired Physician House Calls in Denver, Colorado. Terms of the transaction were not disclosed. Kindred House Calls is also integrating two primary care practices that were part of Gentiva Health Services, acquired in February. The Gentiva practices are located in Austin, Texas, and Spokane, Washington.
08:02 EDTCYHHealthcare Facilities sector upgraded to Attractive at Morgan Stanley
Subscribe for More Information
May 13, 2015
11:47 EDTCVSCVS Health says to pay $22M in settlement with DEA, USAO
CVS Health said in a regulatory filing that it has entered into an agreement with the U.S. Attorney’s Office for the Middle District of Florida and the U.S. Drug Enforcement Administration to resolve previously-disclosed allegations relating to the dispensing of certain controlled substances in Florida. CVS Health agreed to pay $22M and the settlement resolves all civil matters between the Company and the DEA in the state of Florida. This payment amount has been fully accrued for in prior fiscal periods.
10:40 EDTBAXBaxter to host two day investor meeting
Two day Investor meeting to be held in New York May 18-19.
07:07 EDTEBSSoligenix signs development agreement with Emergent BioSolutions
Subscribe for More Information
07:07 EDTEBSGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
May 12, 2015
09:02 EDTBAXBaxter expects to establish BioScience business as separate business by mid-year
Subscribe for More Information
09:01 EDTBAXBaxter to acquire Oncaspar product portfolio from Sigma-Tau for $900M
Subscribe for More Information
08:48 EDTPRGOPerrigo acquires Patheon's Mexican operations for $34M
Subscribe for More Information
07:06 EDTBAXKamada sees FY15 revenue $70M-$73M, consensus $78.69M
Kamada (KMDA) sees revenue from its Distributed Product Segment projected to be between $26 million and $28 million and revenue from its Proprietary Products Segment projected to be between $45 million and $47 million. The company notes that revenue projections for 2015 take into account an expected negative foreign exchange impact of approximately $2.0 million in relation to product sales in Israel and Russia, and presume that U.S. revenue from the agreement with Baxter (BAX) remains on track.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use